Evidence map›Paper›PMID 28233268›Full record

Observational studyClinical research in cardiology supplements2017

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

V J J Schettler, C L Neumann, C Peter, T Zimmermann, U Julius, E Roeseler, F Heigl, P Grützmacher, H Blume, A Vogt and 1 more

Erratum issuedOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical research in cardiology supplements, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Apheresis: What Should a Clinician Know?Current atherosclerosis reports · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Current Role of Lipoprotein Apheresis.Current atherosclerosis reports · 2019
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

V J J SchettlerCenter of Nephrology Göttingen GbR, An der Lutter 24, 37075, Göttingen, Germany. v.schettler@nz-goe.de.
C L NeumannBRAVE e Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e. V., Göttingen, Germany.
C PeterBioArtProducts GmbH (B.A.P.), Rostock, Germany.
T ZimmermannBioArtProducts GmbH (B.A.P.), Rostock, Germany.
U JuliusDepartment of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
E RoeselerCenter for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany.
F HeiglMedical Care Centre Kempten-Allgäu, Kempten, Germany.
P GrützmacherDepartment of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany.
H BlumeScientific Institute for Nephrology (WiNe), Düsseldorf, Germany.
A VogtMedizinische Klinik und Poliklinik 4, Universität München, Munich, Germany.
Scientific Board of GLAR for the German Apheresis Working Group
Kempten University of Applied Sciences · DEUniversity Hospital Carl Gustav Carus · DEAgaplesion Markus Hospital · DEFraunhofer Institute for Cell Therapy and Immunology · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology and of Lipidologists and completed the data set for the registry according to the current guidelines and the German indication guideline for apheresis in 2009. In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 5 years now. METHODS AND

resultsDuring the time period 2012-2016, 71 German apheresis centers collected retrospective and prospective observational data of 1435 patients undergoing lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from cardiovascular disease (CVD) or progressive CVD. A total of 15,527 completely documented LA treatments were entered into the database. All patients treated by LA showed a median LDL-C reduction rate of 67.5%, and a median Lp (a) reduction rate of 71.1%. Analog to the Pro(a)LiFe pattern, patient data were analyzed to the incidence rate of coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y‑1) and prospectively two years on LA treatment (y + 1 and y + 2). During two years of LA treatment a MACE reduction of 78% was observed. In the years considered, side effects of LA treatment were low (5.9%) and mainly comprised puncture problems.

conclusionsThe data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp (a) levels, progressive CVD, and maximally tolerated lipid lowering medication. In addition, LA treatments were found to be safe with a low rate of side effects.

Indexed as

Blood Component RemovalAdultAgedAged, 80 and overBiomarkersCardiovascular DiseasesCholesterol, LDLFemaleGermanyHumansHyperlipoproteinemiasIncidenceLipoprotein(a)MaleMiddle AgedProspective StudiesBiomarkersCholesterol, LDLLipoprotein(a)Coronary heart diseaseLipoprotein apheresisLipoprotein apheresis registryPreventionRisk reduction

Identifiers

PMID28233268
PMCPMC5352787
OpenAlexW2591101840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.